Evidence map›Paper›PMID 26183928›Full record

ArticleCancer research2015

Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung.

Shuguang Leng, Guodong Wu, Leonard B Collins, Cynthia L Thomas, Carmen S Tellez, Andrew R Jauregui, Maria A Picchi, Xiequn Zhang, Daniel E Juri, Dhimant Desai and 9 more

Abstract read
In one paragraph

Article in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Genetic and epigenetic landscape of OExploration of targeted anti-tumor therapy · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 1 country.

Shuguang LengLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Guodong WuLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Leonard B CollinsDepartment of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Cynthia L ThomasLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Carmen S TellezLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Andrew R JaureguiLung Fibrosis Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Maria A PicchiLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Xiequn ZhangLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Daniel E JuriLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Dhimant DesaiDepartment of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania.
Shantu G AminDepartment of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania.
Richard E CrowellDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico.
Christine A StidleyDepartment of Internal Medicine, University of New Mexico, Albuquerque, New Mexico.
Yushi LiuLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
James A SwenbergDepartment of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Yong LinLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Marc G WatheletLung Fibrosis Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico.
Frank D GillilandKeck School of Medicine, University of Southern California, Los Angeles, California.
Steven A BelinskyLung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, New Mexico. sbelinsk@LRRI.org.
Lovelace Respiratory Research Institute · USPenn State Milton S. Hershey Medical Center · USUniversity of New Mexico · USUniversity of North Carolina at Chapel Hill · USUniversity of Southern California · US

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Translational Research Support CoreP30ES007048 · NIEHS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROB S MCCONNELL · 1996 to 2026
$46.4M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel · 2001 to 2026
$36.3M
Factors for Epigenetic Silencing of Lung Cancer GenesR01CA097356 · NCI · LOVELACE BIOMEDICAL & ENVIRONMENTAL RESEARCH INSTITUTE · PI BELINSKY, STEVEN A · 2004 to 2014
$6.3M
MARKERS FOR LUNG CARCINOGENESIS IN BRONCHIAL EPITHELIUMR01CA070190 · NCI · LOVELACE BIOMEDICAL &ENVIRONMENTAL RES · PI BELINSKY, STEVEN A · 1997 to 2001
$892k
NCI NIH HHS P30 CA118100NCI NIH HHS R01 CA070190NCI NIH HHS R01 CA097356NIEHS NIH HHS P30 ES007048NIEHS NIH HHS P30 ES010126NIEHS NIH HHS P30-ES10126
6 · The paper itself

Abstract

O(6)-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that protects cells from carcinogenic effects of alkylating agents; however, MGMT is silenced by promoter hypermethylation during carcinogenesis. A single-nucleotide polymorphism (SNP) in an enhancer in the MGMT promoter was previously identified to be highly significantly associated with risk for MGMT methylation in lung cancer and sputum from smokers. To further genetic investigations, a genome-wide association and replication study was conducted in two smoker cohorts to identify novel loci for MGMT methylation in sputum that were independent of the MGMT enhancer polymorphism. Two novel trans-acting loci (15q15.2 and 17q24.3) that were identified acted together with the enhancer SNP to empower risk prediction for MGMT methylation. We found that the predisposition to MGMT methylation arising from the 15q15.2 locus involved regulation of the ubiquitin protein ligase E3 component UBR1. UBR1 attenuation reduced turnover of MGMT protein and increased repair of O6-methylguanine in nitrosomethylurea-treated human bronchial epithelial cells, while also reducing MGMT promoter activity and abolishing MGMT induction. Overall, our results substantiate reduced gene transcription as a major mechanism for predisposition to MGMT methylation in the lungs of smokers, and support the importance of UBR1 in regulating MGMT homeostasis and DNA repair of alkylated DNA adducts in cells.

Indexed as

Base SequenceChromosomes, Human, Pair 15DNA MethylationDNA Modification MethylasesDNA Repair EnzymesEpithelial CellsFemaleGene Expression RegulationGenetic Predisposition to DiseaseGenome-Wide Association StudyGuanineHumansLongitudinal StudiesLung NeoplasmsMaleMethylationDNA Modification MethylasesDNA Repair EnzymesGuanineMethylnitrosoureaMGMT protein, humanO-(6)-methylguanineTumor Suppressor ProteinsUbiquitin-Protein LigasesUBR1 protein, human

Identifiers

PMID26183928
PMCPMC4526392
OpenAlexW1868950942

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.